JavaScript is disabled for your browser. Some features of this site may not work without it.

    Listar

    Todo RIUMAComunidades & ColeccionesPor fecha de publicaciónAutoresTítulosMateriasTipo de publicaciónCentrosDepartamentos/InstitutosEditoresEsta colecciónPor fecha de publicaciónAutoresTítulosMateriasTipo de publicaciónCentrosDepartamentos/InstitutosEditores

    Mi cuenta

    AccederRegistro

    Estadísticas

    Ver Estadísticas de uso

    DE INTERÉS

    Datos de investigaciónReglamento de ciencia abierta de la UMAPolítica de RIUMAPolitica de datos de investigación en RIUMAOpen Policy Finder (antes Sherpa-Romeo)Dulcinea
    Preguntas frecuentesManual de usoContacto/Sugerencias
    Ver ítem 
    •   RIUMA Principal
    • Investigación
    • Ponencias, Comunicaciones a congresos y Pósteres
    • Ver ítem
    •   RIUMA Principal
    • Investigación
    • Ponencias, Comunicaciones a congresos y Pósteres
    • Ver ítem

    Metabolic changes upon GLS inhibition by CB-839 in glioma cell lines

    • Autor
      Santos Jiménez, Juan de los; Rosales, Tracy; Ko, Bookyung; Márquez-Gómez, JavierAutoridad Universidad de Málaga; Berardinis, Ralph J. de; Mates-Sánchez, José ManuelAutoridad Universidad de Málaga
    • Fecha
      2012-07-19
    • Palabras clave
      Gliomas; Cáncer
    • Resumen
      Many tumors use Gln for both energy generation and as a biosynthetic precursor. Glutaminases (GAs) catalyze the first step of glutaminolysis by converting glutamine (Gln) into glutamate and ammonia in the mitochondria. In humans, two genes encode for glutaminases: GLS and GLS2. We examined the metabolic consequences of inhibiting GLS activity in glioma cells by using the clinically relevant inhibitor CB-839. We treated three glioblastoma (GBM) cell lines with CB-839 and performed untargeted metabolomics and isotope tracing experiments using U-13C-labeled Gln and 15N-labeled Gln in the amido group to ascertain the metabolic fates of Gln carbon and nitrogen. Untargeted metabolomics results showed that CB-839 treatment significantly depleted tricarboxylic acid cycle (TCAC) intermediates and related metabolites in the three human glioblastoma cell lines assayed. This result was also confirmed by a lower labeling from U-13C- Gln in these metabolites. U-13C- Gln tracing also revealed reductive carboxylation-related labeling in these cell lines, and this pathways was also suppressed by CB-839. Metabolomics results showed an accumulation of the de novo purine biosynthesis intermediates inosine monophosphate and/or AICAR, and a decrease in uridine monophosphate, while 15N-Gln tracing results showed a decreased labeling from Gln amido group in AMP, GMP, UMP and CTP in T98G cell line when treated with CB-839. Finally, metabolomics showed higher levels of trimethyllysine and, in T98G cells, a 22-fold increase in 5-methyl-cytosine.
    • URI
      https://hdl.handle.net/10630/24923
    • Compartir
      RefworksMendeley
    Mostrar el registro completo del ítem
    Ficheros
    Metabolic changes upon GLS inhibition by CB-839 DEF (1).pdf (2.949Mb)
    Colecciones
    • Ponencias, Comunicaciones a congresos y Pósteres

    Estadísticas

    Buscar en Dimension
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
     

     

    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA